127
Views
3
CrossRef citations to date
0
Altmetric
Brief Report

Longitudinal evaluation of pharmacists’ social distance preference and attitudes toward patients with opioid misuse following an educational training program

, PharmD, BCPPORCID Icon, , PhD, CPHORCID Icon, , PharmDORCID Icon, , PharmDORCID Icon, , PharmDORCID Icon & , PharmD, MPHORCID Icon

References

  • Link BG, Yang LH, Phelan JC, Collins PY. Measuring mental illness stigma. Schizophr Bull. 2004;30(3):511–541.
  • Corrigan P, Schomerus G, Shuman V, et al. Developing a research agenda for understanding the stigma of addictions part I: lessons from the mental health stigma literature. Am J Addict. 2017;26(1):59–66.
  • Livingston JD, Milne T, Fang ML, Amari E. The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. Addiction. 2012;107(1):39–50.
  • Weiss MG, Ramakrishna J, Somma D. Health-related stigma: rethinking concepts and interventions. Psychol Health Med. 2006;11(3):277–287.
  • Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC. The stigma of alcohol dependence compared with other mental disorders: a review of population studies. Alcohol Alcohol. 2011;46(2):105–112.
  • Giandinoto J-A, Stephenson J, Edward K-L. General hospital health professionals' attitudes and perceived dangerousness towards patients with comorbid mental and physical health conditions: systematic review and meta-analysis. Int J Ment Health Nurs. 2018;27(3):942–955.
  • Henderson C, Noblett J, Parke H, et al. Mental health-related stigma in health care and mental health-care settings. Lancet Psychiatry. 2014;1(6):467–482.
  • Rao H, Mahadevappa H, Pillay P, Sessay M, Abraham A, Luty J. A study of stigmatized attitudes towards people with mental health problems among health professionals. J Psychiatr Ment Health Nurs. 2009;16(3):279–284.
  • Corrigan PW, Mittal D, Reaves CM, et al. Mental health stigma and primary health care decisions. Psychiatry Res. 2014;218(1–2):35–38.
  • O'Reilly CL, Bell JS, Kelly PJ, Chen TF. Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. Res Social Adm Pharm. 2015;11(3):e101–e109.
  • van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1–2):23–35.
  • Centers for Disease Control and Prevention. Health Alert Network (HAN). https://emergency.cdc.gov/han/2020/han00438.asp?ACSTrackingID=USCDC_511-DM44961&ACSTrackingLabel=HAN%20438%20-%20General%20Public&deliveryName=USCDC_511-DM44961. Published December 17, 2020. Accessed September 8, 2021.
  • Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176.
  • Crapanzano K, Vath RJ, Fisher D. Reducing stigma towards substance users through an educational intervention: harder than it looks. Acad Psychiatry. 2014;38(4):420–425.
  • Brener L, Cama E, Hull P, Treloar C. Evaluation of an online injecting drug use stigma intervention targeted at health providers in New South Wales, Australia. Health Psychol Open. 2017;4(1):2055102917707180.
  • Bland E, Oppenheimer LW, Oppenheimer L, et al. Influence of an educational program on medical students’ attitudes to substance use disorders in pregnancy. Am J Drug Alcohol Abuse. 2001;27(3):483–490.
  • Hayes SC, Bissett R, Roget N, et al. The impact of acceptance and commitment training and multicultural training on the stigmatizing attitudes and professional burnout of substance abuse counselors. Behavior Therapy. 2004;35(4):821–835.
  • Corrigan PW, Schomerus G, Shuman V, et al. Developing a research agenda for reducing the stigma of addictions, part II: lessons from the mental health stigma literature. Am J Addict. 2017;26(1):67–74.
  • Corrigan PW, Nieweglowski K. Stigma and the public health agenda for the opioid crisis in America. Int J Drug Policy. 2018;59:44–49.
  • McGinty EE, Goldman HH, Pescosolido B, Barry CL. Portraying mental illness and drug addiction as treatable health conditions: effects of a randomized experiment on stigma and discrimination. Soc Sci Med. 2015;126:73–85.
  • Broyles LM, Binswanger IA, Jenkins JA, et al. Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. Subst Abuse. 2014;35(3):217–221.
  • Stier A, Hinshaw DSP. Explicit and implicit stigma against individuals with mental illness. Aust Psychol. 2007;42(2):106–117.
  • Stigma-reducing language. Shatterproof. https://www.shatterproof.org/about-addiction/stigma/stigma-reducing-language. Accessed September 8, 2021.
  • Brown SA. Standardized measures for substance use stigma. Drug Alcohol Depend. 2011;116(1–3):137–141.
  • Wark C, Galliher JF. Emory Bogardus and the origins of the Social Distance Scale. Am Soc. 2007;38(4):383–395.
  • Pescosolido BA, Medina TR, Martin JK, Long JS. The “Backbone” of stigma: identifying the global core of public prejudice associated with mental illness. Am J Public Health. 2013;103(5):853–860.
  • Lien Y-Y, Lin H-S, Tsai C-H, Lien Y-J, Wu T-T. Changes in attitudes toward mental illness in healthcare professionals and students. IJERPH. 2019;16(23):4655.
  • Bahora M, Hanafi S, Chien VH, Compton MT. Preliminary evidence of effects of crisis intervention team training on self-efficacy and social distance. Adm Policy Ment Health. 2008;35(3):159–167.
  • Eukel HN, Skoy E, Werremeyer A, Burck S, Strand M. Changes in pharmacists’ perceptions after a training in opioid misuse and accidental overdose prevention. J Contin Educ Health Prof. 2019;39(1):7–12.
  • Strand MA, Eukel H, Frenzel O, Skoy E, Steig J, Werremeyer A. Program evaluation of the Opioid and Naloxone Education (ONE Rx) program using the RE-AIM model. Res Social Adm Pharm. 2020;16(9):1248–1254.
  • Strand MA, Eukel H, Burck S. Moving opioid misuse prevention upstream: a pilot study of community pharmacists screening for opioid misuse risk. Res Social Adm Pharm. 2019;15(8):1032–1036.
  • Skoy E, Eukel H, Werremeyer A, Strand M, Frenzel O, Steig J. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose. J Am Pharm Assoc. 2020;60(1):117–121.
  • The ONE Program – Opioid and Naloxone Education. https://one-program.org/. Accessed September 8, 2021.
  • Eukel H, Steig J, Frenzel O, Skoy E, Werremeyer A, Strand M. Opioid misuse and overdose: changes in pharmacist practices and outcomes. J Contin Educ Health Prof. 2020;40(4):242–247.
  • Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432–442.
  • Kelly JF, Saitz R, Wakeman S. Language, substance use disorders, and policy: the need to reach consensus on an “Addiction-ary”. Alcohol Treat Q. 2016;34(1):116–123.
  • Crocker AF, Smith SN. Person-first language: are we practicing what we preach? J Multidiscip Healthc. 2019;12:125–129.
  • Peyser A, Gerard F-M, Roegiers X. Implementing a pedagogy of integration: Some thoughts based on a textbook elaboration experience in Vietnam. Plan Changing 2006;37:37–55.
  • Penn DL, Guynan K, Daily T, Spaulding WD, Garbin CP, Sullivan M. Dispelling the stigma of schizophrenia: what sort of information is best? Schizophr Bull. 1994;20(3):567–578.
  • Ritsher JB, Phelan JC. Internalized stigma predicts erosion of morale among psychiatric outpatients. Psychiatry Res. 2004;129(3):257–265.
  • Subramaniam M, Abdin E, Picco L, et al. Stigma towards people with mental disorders and its components – a perspective from multi-ethnic Singapore. Epidemiol Psychiatr Sci. 2017;26(4):371–382.
  • Tay S, Alcock K, Scior K. Mental health problems among clinical psychologists: stigma and its impact on disclosure and help-seeking. J Clin Psychol. 2018;74(9):1545–1555.
  • Werremeyer A, Mosher S, Eukel H, et al. Pharmacists’ stigma toward patients engaged in opioid misuse: when ‘social distance’ does not mean disease prevention. Subst Abus. 2021;42(4):919–926.
  • Worley-Louis MM, Schommer JC, Finnegan JR. Construct identification and measure development for investigating pharmacist–patient relationships. Pat Educ Couns. 2003;51(3):229–238.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.